SG11201407309XA - Compositions and methods for the treatment of epilepsy - Google Patents

Compositions and methods for the treatment of epilepsy

Info

Publication number
SG11201407309XA
SG11201407309XA SG11201407309XA SG11201407309XA SG11201407309XA SG 11201407309X A SG11201407309X A SG 11201407309XA SG 11201407309X A SG11201407309X A SG 11201407309XA SG 11201407309X A SG11201407309X A SG 11201407309XA SG 11201407309X A SG11201407309X A SG 11201407309XA
Authority
SG
Singapore
Prior art keywords
disorder
international
formula
epilepsy
seizures
Prior art date
Application number
SG11201407309XA
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of SG11201407309XA publication Critical patent/SG11201407309XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/167986 A2 (51) International Patent Classification: Not classified (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/IB2013/050740 29 January 2013 (29.01.2013) English English (30) Priority Data: 1791/CHE/2012 8 May 2012 (08.05.2012) IN (72) Inventor; and (71) Applicant : KANDULA, Mahesh [IN/IN]; Door No. 11- 61, Samalkot Mandal, East Godavari Dist, G.Medapadu 533 434, Andhra Pradesh (IN). (72) Inventor: KANDULA, Mahesh; Door No. 11-61, East Godavari Dist, Samalkot Mandal, Andhra Pradesh, G.medapadu 533434 (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) CJ 00 as i-H cn i-H o CJ o & (54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY (57) Abstract: The invention relates to the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I) or formula (II); and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such composi - tions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder, partial seizures, adjunctive therapy for partial, myoclonic, tonic-clonic seizures and schizophrenia, neuropathic pain, seizures, Tourette syn­ drome, Alzheimer's disease, autism, bipolar disorder and anxiety disorder, bipolar disorder, mania, phantom limb syndrome, com - plex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotoaia, intermittent explosive disorder, borderline person­ ality disorder, myotonia congenita and post-traumatic stress disorder.
SG11201407309XA 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy SG11201407309XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1791CH2012 2012-05-08
PCT/IB2013/050740 WO2013167986A2 (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy

Publications (1)

Publication Number Publication Date
SG11201407309XA true SG11201407309XA (en) 2014-12-30

Family

ID=54187089

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407309XA SG11201407309XA (en) 2012-05-08 2013-01-29 Compositions and methods for the treatment of epilepsy

Country Status (7)

Country Link
EP (1) EP2846795A2 (en)
JP (1) JP2015526385A (en)
AU (1) AU2013257707A1 (en)
CA (1) CA2873016A1 (en)
SG (1) SG11201407309XA (en)
WO (1) WO2013167986A2 (en)
ZA (1) ZA201408058B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379589A (en) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 Prodrugs of anti-platelet agents
CA2873018A1 (en) * 2012-07-03 2014-01-09 Cellixbio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2015184542A1 (en) * 2014-06-02 2015-12-10 Ketogen Inc. Compounds for the treatment of seizures and other central nervous system disorders and conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL183678B1 (en) * 1995-05-05 2002-06-28 Novo Nordisk As Pharmaceutic agent containing thiagabine chlorhydride and method of obtaining same
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
US8338621B2 (en) * 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
WO2010132693A2 (en) * 2009-05-13 2010-11-18 Nektar Therapeutics Oligomer-containing pyrrolidine compounds

Also Published As

Publication number Publication date
CA2873016A1 (en) 2013-11-14
AU2013257707A1 (en) 2014-11-27
WO2013167986A3 (en) 2015-06-18
EP2846795A2 (en) 2015-03-18
JP2015526385A (en) 2015-09-10
ZA201408058B (en) 2016-03-30
WO2013167986A2 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
SG11201408094YA (en) Neprilysin inhibitors
SG11201805838UA (en) Macrocyclic mcl1 inhibitors for treating cancer
SG11201805380YA (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
SG11201407326XA (en) Compositions and methods for treatment of mucositis
SG11201809625RA (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
SG11201407533SA (en) Antiviral compounds
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407596TA (en) Conjugation reagents
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201408629QA (en) Dimethyl-benzoic acid compounds
SG11201408261UA (en) Syringe
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201808220VA (en) Allosteric modulators of nicotinic acetylcholine receptors
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201407189XA (en) C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201408224SA (en) Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201407303SA (en) Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201407591PA (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SG11201407317SA (en) Compositions and methods for suppression of carbonic anhydrase activity
SG11201407934UA (en) Camsylate salt